[{"orgOrder":0,"company":"Adimmune","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Adimmune May Start COVID-19 Vaccine Clinical Trials in August","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"TAIWAN","productType":"Vaccine","productStatus":"Undisclosed","date":"May 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"Adimmune","sponsor":"Eden Biologics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"JHL Biotech to Develop and Manufacture GMP-grade Antigen for Taiwan\u2019s Leading Covid-19 Vaccine Produced by Adimmune","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"N\/A","country":"TAIWAN","productType":"Vaccine","productStatus":"Undisclosed","date":"September 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"N\/A"},{"orgOrder":0,"company":"Adimmune","sponsor":"Clover Biopharmaceuticals","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Clover Enters into Exclusive Agreement to Commercialize Quadrivalent Seasonal Influenza Vaccine in Mainland China","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase IV","country":"TAIWAN","productType":"Vaccine","productStatus":"Approved","date":"February 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase IV"}]
Find Clinical Drug Pipeline Developments & Deals by Adimmune
Under the terms of the agreement, Clover gains commercial rights to AdimFlu-S (quadrivalent influenza vaccine) in mainland China, Bangladesh, Brazil and the Philippines. AdimFlu-S is a quadrivalent split inactivated vaccine intended for use in the prevention of influenza.
Under the terms of the Master Service Agreement, JHL Biotech will support Adimmune Corporation to manufacture and supply the Antigen for their leading Covid-19 vaccine candidate.
Adimmune had designed and produced 4 prototypes of antigens to fight Covid-19 based on its recombinant protein technology, and has tested one prototype in a BSL-3 lab at National Taiwan University.